

AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasani Road, Andheri East, Mumbai 400 093

UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30,2010

Rs. Million

Particulars	Quarter ended	Quarter ended	Nine Months ended	Nine Months ended	Year ended
	30.09.2010 Unaudited	30.09.2009 Unaudited	30.09.2010 Unaudited	30.09.2009 Unaudited	31.12.2009 (Audited)
1.(a) Net Sales	2,756	2,585	7,985	7,373	9,744
(b) Other Operating Income	180	190	539	585	781
Total	2,936	2,775	8,524	7,958	10,525
2 Expenditure					
(a) (Increase)/decrease in stock in trade and work in progress	(238)	(178)	(68)	(387)	(623)
(b) Consumption of raw materials	943	848	2,588	2,783	3,525
(c) Purchase of traded goods	618	595	1,432	1,196	1,918
(d) Employees cost	394	380	1,178	1,058	1,440
(e) Depreciation	53	44	143	129	173
(f) Other expenditure	614	644	1,631	1,428	2,006
(g) Total	2,384	2,233	6,904	6,187	8,439
3 Profit from Operations before Other Income and Interest (1-2)	552	542	1,620	1,771	2,086
4 Other Income	133	99	253	273	330
5 Profit before Interest (3+4)	685	641	1,873	2,044	2,416
6 Interest	-	-	-	-	1
7 Profit before tax (5-6)	685	641	1,873	2,044	2,415
8 Tax expense	212	203	615	730	841
9 Net Profit for the period (7-8)	473	438	1,258	1,314	1,574
10 Paid-up equity share capital (Face Value of Rs. 10 per share)	230	230	230	230	230
11 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year					8,916
12 Earnings Per Share (EPS) (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	20.57	19.04	54.70	57.13	68.35
13 Public Shareholding					
- Number of Shares	9,121,035	9,120,955	9,121,035	9,120,955	9,120,955
- Percentage of Shareholding	39.60%	39.60%	39.60%	39.60%	39.60%
14 Promoters and Promoter group Shareholding					
a) Pledged/Encumbered					
- Number of shares	NIL	2,366,920	NIL	2,366,920	2,366,920
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	17.01%	NIL	17.01%	17.01%
- Percentage of shares (as a % of total share capital of the company)	NIL	10.27%	NIL	10.27%	10.27%
b) Non-encumbered					
- Number of shares	13,909,587	11,543,747	13,909,587	11,543,747	11,543,747
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100.00%	82.99%	100.00%	82.99%	82.99%
- Percentage of shares (as a % of total share capital of the company)	60.40%	50.13%	60.40%	50.13%	50.13%

A 02 ED

Notes:

1. The above results were approved by the Board of Directors of the Company at its Meeting held on October 25, 2010.
2. In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the nine months ended September 30, 2010.
3. The Board of Directors had declared an Interim Dividend of Rs. 4 per Equity share of Rs 10 for the year ending December 31, 2010. The dividend (including Dividend Distribution Tax) amounted to Rs.107 million. The said dividend was paid on August 9, 2010 through National Electronic Clearing Service /Dividend Warrants.
4. The break up of Net Sales is as follows:

Rs Million						
	Quarter ended Sept 30, 2010	Quarter ended Sept 30, 2009	Growth %	Nine Months ended Sept 30, 2010	Nine Months ended Sept 30, 2009	Growth %
Domestic Sales-Others	2,320	2,025	14.6%	6,469	5,534	16.9%
Domestic Sales-Rabipur	-	-	-	-	92	-100.0%
Export Sales	436	560	-22.1%	1,516	1,747	-13.2%
Total Sales	2,756	2,585	6.6%	7,985	7,373	8.3%

Excluding the impact of discontinuation of Rabipur distribution, comparable sales growth for the nine months ended September 30, 2010 is 9.7%.

5. Throughout 2010, the Company will incur planned expenditure in two critical projects-slated to be growth drivers :
 - a) "Prayas"- a project to deliver high quality low cost healthcare to the rural population ; and
 - b) Entering the Over The Counter (OTC) market.


These initiatives are expected to deliver long term prospects for the Company.

6. The Company has a single business segment namely 'Pharmaceutical Business'.
7. Information on investor complaints is furnished below:

Pending as on July 1, 2010	Received during the quarter	Disposed of during the quarter	Pending as on September 30, 2010
Nil	2	2	Nil

8. The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED



**DR. SHAILESH AYYANGAR
MANAGING DIRECTOR**

October 25, 2010

